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Abstract 
Objectives: The imaging of dopamine D2 receptors is essential for the diagnostic 
assessment of diseases in which the dopaminergic system is affected. (e.g. Parkinson‟s 
disease, Chorea Huntington and schizophrenia) 
 
First generation dopamine D2 radiotracers like [
123I]IBZM and [11C]Raclopride showed 
only moderate affinity towards the dopamine D2 receptor, making the imaging of these 
receptors in extrastriatal brain areas impossible. High-affinity dopamine D2 receptor 
tracers like [18F]Fallypride have been designed to make extrastriatal dopamine D2 
receptors accessible to PET neuroimaging. 
 
This diploma thesis focuses on the optimization of two radiosynthesic approaches for the 
synthesis of [18F]Fallypride. The first approach was „conventional“ vial-based 
radiosynthesis, while in the second approach a microfluidic chemistry device (the 
Advion® NanoTek LF) was used. Furthermore, radio-TLC (thin layer chromatography) 
and radio-HPLC (high pressure liquid chromatography) assays were developed to 
detect, identify and quantify [18F]fluoride, [18F]Fallypride and potential by-products of the 
synthesis. 
 
Methods: [18F]fluoride was obtained in its aqueous solution by irradiation of [18O]water  
in a GE PETtrace medical cyclotron utilising the 18O (p,n) 18F nuclear reaction. To 
increase its nucleophilicity, [18F]fluoride was separated from [18O]water by adsorption 
onto an anion exchange cartridge. [18F]fluoride was transferred into the organic phase 
through elution with a solution of potassium carbonate and the phase transfer catalyst 
Kryptofix 2.2.2. in water / acetonitrile (70/30 v/v%). Trace water was then removed by 
azeotropic drying and re-solution of [18F]fluoride in acetonitrile under inert gas 
atmosphere. 
 
[18F]Fallypride was synthesized from its tosylate precursor by nucleophilic substitution of 
the tosylate group by means of (1) addition of a solution of [18F]fluoride to a solution of 
the tosylate precursor and subsequent heating in a glass vial. (2) using a novel 
microfluidic synthesis device. Reactions were performed within this microfluidic system 
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by simultaneously pushing [18F]fluoride and tosylate precursor through the fused-silica 
micro-reactor. 
 
The radiosynthesis of [18F]Fallypride was evaluated in respect to optimal reaction 
conditions (e.g. concentration, reaction duration and reaction temperature) for both 
approaches. 
 
Results: Optimum reaction conditions for the vessel-based synthesis of [18F]Fallypride 
were a precursor concentration of 2.5mg/mL and a reaction duration of 30 minutes at a 
temperature of 70°C, yielding 35.6±4.2% of the product [18F]Fallypride. For microfluidic 
syntheses, ideal reaction conditions were a precursor concentration of 2.5mg/mL at a 
reaction temperature of 180°C and a flow rate of 30µL/min per pump (60µL/min overall 
flow rate), yielding 91.6±1.0% of the product [18F]Fallypride.  
 
Conclusion: Optimized reaction conditions and quality control procedures for the 
synthesis of [18F]Fallypride have been established for the classic vessel-based approach 
as well as the microfluidic synthesis approach. Very high yields, low precursor usage 
and short reaction times of microfluidic reactions show the importance of this emerging 
new technique in radiosynthesis, especially for hardly available and expensive 
precursors. 
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Zusammenfassung 
Ziele: Die Bildgebung von Dopamin D2-Rezeptoren ist essentiell für die 
nuklearmedizinische Diagnostik von Erkrankungen mit Beteiligung des dopaminergen 
Systems wie der Parkinson‟schen Krankheit, Chorea Huntington und der Schizophrenie. 
 
Da Dopamin D2 Rezeptortracer der ersten Generation wie [
123I]IBZM oder 
[11C]Raclopride nur moderate Affinitäten zum D2-Rezeptor zeigen, war mit diesen 
Substanzen eine Darstellung von D2-Rezeptoren in extrastriatalen Hirnarealen nicht 
möglich. Hochaffine D2-Liganden wie [
18F]Fallypride ermöglichen hingegen die 
Darstellung von D2-Rezeptoren in diesen Gehirnarealen. 
 
Diese Diplomarbeit beschäftigt sich mit der Optimierung zweier Ansätze zur Synthese 
des PET-Radiotracers [18F]Fallypride. Zuerst wurde [18F]Fallypride mittels 
nasschemischer Methoden synthetisiert. Danach erfolgte die Synthese von 
[18F]Fallypride mittels eines neuartigen Mikrofluidsystems, dem Advion®  NanoTek LF. 
Weiters wurden ein radio-dünnschichtchromatographisches Verfahren und eine radio-
HPLC-Methode für die Qualitätskontrolle und zur Erkennung potentieller 
Verunreinigungen entwickelt. 
 
Methoden: [18F]Fluorid wurde in einem GE PETtrace-Zyklotron durch Bestrahlung von 
[18O]Wasser unter Anwendung der 18O (p,n) 18F-Kernreaktion in wässriger Lösung 
gewonnen. Um die Nukleophilie des [18F]Fluorids zu erhöhen, wurde es durch 
Adsorption an eine Anionenaustauscherkartusche von [18O]Wasser abgetrennt und 
mittels einer Lösung aus Kaliumcarbonat und dem Phasentransferkatalysator Kryptofix 
K.2.2.2 in  Acetonitril/Wasser (70:30 v/v%) in die organische Phase übergeführt. Durch 
azeotrope Trocknung unter Inertgas wurden letzte Wasserspuren entfernt. 
 
[18F]Fallypride wurde sodann durch nukleophile Substitution der Tosylatgruppe aus dem 
Precursor tosyl-Fallypride synthetisiert, indem eine Lösung von getrocknetem 
[18F]Fluorid zu einer Lösung des Precursors hinzugegeben und in einem 
Aluminiumheizblock erhitzt wurde. Die Synthese von [18F]Fallypride im Mikroreaktor 
erfolgte durch gleichzeitiges Einleiten von [18F]Fluorid und der Vorläufersubstanz tosyl-
Fallypride in den erhitzten Mikroreaktor. 
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Die Radiosynthese von [18F]Fallypride wurde für beide Ansätze hinsichtlich optimaler 
Precursorkonzentration, Reaktionsdauer und Reaktionstemperatur evaluiert.  
 
Ergebnisse: Optimale Synthesebedingungen für den nasschemischen Ansatz wurden 
unter Verwendung einer Precursorkonzentration von 2.5mg/mL, einer Reaktionsdauer 
von 30min bei einer Reaktionstemperatur von 70°C erzielt. Die radiochemische 
Ausbeute betrug hierbei 35,6±4,2% des Produkts [18F]Fallypride. Für die 
mikrofluidischen Synthesen erwiesen sich eine Precursorkonzentration von 2.5mg/mL 
bei einer Reaktionstemperatur von 180°C und einer Durchflussrate von 30µL/min pro 
Pumpe (Gesamtdurchflussrate: 60µL/min) als ideal, wobei sich sehr hohe Ausbeuten 
von 91.6±1.0% ergaben. 
 
Schlussfolgerung: Sowohl für die klassische “Kessel”-Reaktion als auch für den 
mikrofluiden Ansatz wurden ideale Reaktionsbedingungen für die Synthese von 
[18F]Fallypride etabliert. Ausgezeichnete Ausbeuten, geringer Precursorverbrauch und 
kurze Reaktionszeiten der mikrofluiden Reaktionen verdeutlichen die Wichtigkeit dieser 
Technik für Radiosynthesen, speziell für schwer erhältliche und teure 
Vorläufersubstanzen.  
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1 Introduction 
1.1 Basic considerations on radioactivity 
The analysis of the naturally occurring radioelements Thorium and Radium 
beared the insight that some “elements” are not separable by chemical means. 
[1] This finding led to the concept of isotopes (Greek: “in the same place”). 
Atoms differing by their atomic number or mass number are called nuclides. For 
identification, element symbol and mass number are used. [2] 
 
Fig. 1.1: The chart of the nuclides, graphical depiction of important terms (from [3]) 
Isotopes of an element exhibit the same number of protons in their nuclei, but the 
number of neutrons is different. For this reason the chemical properties of 
isotopes are identical, and they occupy the same place in the periodic table of 
elements. The periodic table does not have room for information about all the 
isotopes. For this reason the chart of nuclides has been designed. In such a 
chart, the nuclides are placed in a diagram: the ordinate represents the number 
of protons (Z) whereas the abscissa represents the number of neutrons (N). 
In the chart of the nuclides, stable nuclides are arranged around a line starting at 
the point of origin. This line, which is called the line of β stability, has the slope 1, 
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which means N equals Z for the nuclides on the line. For heavier nuclides, the 
line is bent towards the abscissa. This is because the nuclear attractive force 
neutrons exert onto other nucleons (the so-called “strong force”) is very short 
ranged (effective only at distances smaller than 2.4fm).[4]  
Neutrons can only interact with their nearest neighbour nucleons. On the 
contrary, the repulsive Coulomb force the positively charged protons exert onto 
each other is much more long-ranged. (decreasing proportionally to 1/r2) For this 
reason, the number of neutrons has to grow faster than the number of protons for 
a nucleus to be stable. 
 
Fig. 1.2: A section of the Karlsruhe nuclide chart, depicting the line of  -stability (black 
boxes) and the different decay modes (red, blue, yellow and white boxes) from [5] 
 
Nuclides not on or near the line of β stability are unstable and decay in various 
modes and are thus called radionuclides. These are color-coded in the chart of 
nuclides (Fig. 1.2). 
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1.2 Radioactive decay 
Radioactive decay is the spontaneous transmutation of an unstable parent 
nucleus into a stable or unstable daughter nucleus, whereas the released energy 
is emitted in the form of α or β particles and/or γ rays. Depending on the 
properties of the nuclide, various decay modes can occur. 
1.2.1   decay 
The process of α decay is found preferably in proton rich, heavier elements due 
to the fact that electrostatic repulsive forces increase more rapidly in heavy 
nuclides than cohesive nuclear forces. [3] These nuclides are coded yellow in the 
Karlsruhe nuclide chart (Fig. 1.2), their mode of decay is described by the 
following equation: 
4 4 2
2 2
A A
Z ZP D He
 
   
Due to their size, α particles are not easily deflected. On their way through tissue, 
α particles cause ionizations through electrostatic attraction of electrons. The α 
particle‟s energy is deposited along the traversed tissue until two electrons are 
captured, leading to the formation of a neutral helium atom. The amount of 
energy deposited per unit distance, called linear energy transfer (LET), is 
however bigger than for β or γ radiation. [6]  
For this reason, the cytotoxicity of α radiation is greater than that of β or γ 
radiation. Additionally, energy deposition of α radiation is locally delimited due to 
the average range of less than 100µm in tissue. [6] 
These advantageous characteristics make α emitters (e.g. Astatine-211) subject 
to intense research as therapeutic nuclides for various applications in 
radiotherapy.  
1.2.2 β--decay 
β--decay is the emission of an electron (β-) and an anti-neutrino ( ) from an 
unstable parent nucleus P. Formally, this process is described as follows: 
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1
A A
Z ZP D v

    
This decay form occurs with nuclei exhibiting an excess of neutrons. In the 
nucleus, a neutron is converted into a proton, an electron β- and a neutrino. To 
emphasize the origin of the electron is the nucleus, it is denoted β- while 
electrons from atomic shells are denoted e-. 
Nuclei decaying through β- decay are coded blue in the Karlsruhe nuclide chart. 
(Fig. 1.2) β--emitters are used as therapy nuclides in targeted radiotherapy. Since 
β- radiation produces very few ionizations along the beam track and almost all 
particle energy is deposited within the last few nanometers of the particle range, 
it allows the locally delimited delivery of high radiation doses to malignant 
tissue.[6] 
An example for a β- emitter is Iodine-131, which is used for the radiotherapy of 
the thyroid. Other beta-minus emitting nuclides are Lutetium-177, Rhenium-188 
and Yttrium-90, all are used in the targeted radiotherapy of malignant diseases. 
1.2.3 β+ decay 
Beta-plus or positron decay occurs with nuclides with an excess of protons. 
These nuclides are color coded red in the Karlsruhe nuclide chart. This process 
is defined by the following equation: 
1
A A
Z ZP D v

    
A proton in the nucleus is converted into a neutron, while a positron β+ (a 
positively-charged electron) and a neutrino are ejected from the nucleus. The 
positron is strongly attracted by the negative charges of adjacent electrons. 
Positron and electron annihilate into two  photons with an energy of 511keV 
each after their collision. These  -photons are then emitted in exactly opposed 
directions although minor deviatons have been reported. [7] 
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Positron emitters as 11C, 13N, 18F or 68Ga are widely used in nuclear medicine, as 
they are the basis for PET imaging, which is discussed in detail in chapter 1.5. 
1.2.4 Electron capture (EC) or ε decay 
Just as β+ decay, EC decay occurs in proton-rich nuclides. A nucleus captures an 
electron from its shell, most commonly the K shell. The core proton and the 
captured electron are converted into a neutron and an electron-neutrino.  
The position of the K shell electron is immediately filled by an electron from a 
higher shell, while the energy difference between the shells is emitted as 
monoenergetic X rays. [8] 
The EC decay process is described by the following equation: 
0 0
1 1 0
A A
Z Z eP e D v

     
1.2.5 γ transitions 
When an unstable nucleus decays through α ,β or EC decay, the daughter 
nucleus will often not result directly in its energetic ground state, but in a state of 
excess energy. Therefore, the nucleus has to emit this excess energy in the form 
of γ rays.  
 
Often this emission consists not only of a single γ quantum but a cascade of γ 
transitions with different transition energies until the ground state is reached. 
Since these states possess discrete energy levels, the emitted γ photons are also 
of discrete energies. 
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When γ rays are detected with a scintillation counter and the count rate is plotted 
versus energy, a γ energy spectrum (e.g. Fig. 1.3) results. Since this spectrum is 
unique for every nuclide, γ spectroscopy can be used for radionuclide 
identification. 
The most prominent applications of γ-emitters in nuclear medicine are 
scintigraphy and SPECT, both are discussed in chapter 1.4.2. 
1.3 Production of radionuclides for nuclear medicine 
Radionuclides used in nuclear medicine are produced artificially either by means 
of nuclear reactors, nuclide generator systems or particle accelerators. 
1.3.1 Radionuclide production via nuclear reactors 
Neutron-rich radionuclides can be obtained by irradiation of the target material 
with a neutron beam. This beam is generated through the fission of heavy, 
neutron-rich nuclides such as 235U in a nuclear reactor. After a 235U nucleus 
captures a neutron, it splits into two medium-weight nuclei, while an average 2.4 
Fig. 1.3: γ energy spectrum of 60Co (from [9]) 
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neutrons are released. [10] These neutrons can subsequently be captured by 
other 235U nuclei and thus sustain the nuclear fission chain reaction. 
Since the reaction cross section (the probability for a nuclear reaction to occur) is 
highest for thermal neutrons with kinetic energy of up to 0.025eV [11], fast 
neutrons (neutrons possessing kinetic energies greater than 100keV) released 
during the nuclear fission reaction have to be decelerated to “thermal” velocities 
with kinetic energy of less than 0.4eV) to increase the probability for nuclear 
reactions. [12] 
For this task a moderator like water, deuterated water or graphite is used. Fast 
neutrons are slowed down to a thermal energy level through collisions with 
moderator atoms. After neutron energy has been reduced to a thermal level, the 
target material can be placed in the neutron beam to obtain the desired 
radionuclide. 
Prominent examples for radionuclides manufactured in nuclear reactors are 3H, 
14C, 131I, 99Mo and 68Ge.  
1.3.2 Radionuclide production via nuclide generators 
Since the importance of 99mTc for medical imaging was recognized, the demand 
for high purity, easy to handle production of 99mTc has been constantly rising. Out 
of this need, Tucker, Richards and Green developed the 99Mo / 99mTc 
radionuclide generator system in 1958. [13] 
In this system, the long-lived mother nuclide 99Mo is adsorbed onto an ion 
exchange resin, steadily decaying into its daughter nuclide 99mTc. When activity 
levels of mother and daughter nuclide reach equilibrium, the generator column is 
eluted with 0.9% saline solution to separate both nuclides from one another.  
During the elution process, the pertechnetate anion [99mTc]TcO4
- is displaced by 
the Cl- anion by means of anion exchange. The activity of daughter nuclide in the 
column is thereby reduced to almost zero. New daughter grows out of the mother 
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nuclide, reaching equilibrium with the mother once again after a certain period of 
time, at which the generator can be eluted again. (shown in Fig. 1.4) 
The available daughter activity decreases linearly with the decay of the mother 
nuclide. Depletion of the mother nuclide marks the end of the generator‟s life-
span. 
Apart from 99mTc used in γ scintigraphy, also some PET nuclides can be obtained 
from generator systems. Gallium-68, which for example is used for the labelling 
of peptides for PET imaging of neuroendocrine tumors can be obtained from its 
mother nuclide 68Ge in the 68Ge / 68Ga generator system. Another example for a 
generator PET nuclide is 82Rb (used for myocardial perfusion studies) obtained 
from 82Kr using the 82Kr / 82Rb generator system. 
 
Fig. 1.4: Activity relationships in a 
99
Mo / 
99m
Tc nuclide generator system (from [14]) 
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For reasons of easy handling and almost instant radionuclide availability, 
generator systems have found a broad application in nuclear medicine, not least 
because of the independence from a costly cyclotron for radionuclide production. 
1.3.3 Radionuclide production via cyclotron 
Common proton-rich PET nuclides like 18F, 11C, 13N or 15O are produced by 
bombarding suitable target nuclei with a proton or deuteron beam in a cyclotron. 
A cyclotron is a circular accelerator comprised of an ion source, a solenoid with 
two D-shaped chambers (“Dees”) between its poles and a chamber containing 
the target material. These chambers are evacuated to prevent loss of kinetic 
energy and unwanted nuclear reactions with nuclei present in the air. 
A uniform magnetic field is applied to force the particles on a semicircular orbit 
within the Dee. Since the Dees are shielded, only the magnetic force can affect 
the particles inside. When the gap between the Dees is reached, the electrical 
field gradient is reversed to accelerate the particles. 
Fig. 1.5: Schematic illustration of a cyclotron particle accelerator (modified after [15]) 
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Since the time a particle needs to traverse its orbit is independent of the orbit 
radius [16] the frequency at which the electrical field phase in the gap changes 
(the cyclotron frequency) can be kept constant throughout the whole acceleration 
process. When the particle beam has gained sufficient energy and orbit radius, it 
reaches a carbon foil which “strips off” electrons from the accelerated H- ions, 
turning them into H+ ions. Since the orientation of the electric field has not 
changed, the H+ ions are being deflected towards the outlet opening and directed 
into the target chamber. 
In the target chamber, the high-energy protons collide with the target material to 
form the desired radionuclide in a transmutation reaction. The most common 
transmutation reaction used in a medical cyclotron is the reaction of oxygen-18 
with a proton to form fluorine-18. [17] This transmutation reaction is shown in Fig. 
1.6. 
 
 
1.4 Conventional Nuclear Imaging 
Nuclear medicine uses radioactive compounds for diagnostic or therapeutic 
applications. These methods often allow the diagnosis of a disease before 
morphologic changes in body tissue become visible.  
The major difference between the techniques of nuclear medicine and other 
imaging techniques is that the former deliver functional information, while the 
latter deliver structural information about the examined tissue or organ. In 
conjunction with other imaging techniques, a comprehensive picture of the organ 
status, structural and functional, can be gained. 
Conventional imaging techniques include ultrasound, x-ray, computed 
tomography (CT) and magnetic resonance tomography (MRT). Nuclear imaging 
techniques include scintigraphy, single photon computed tomography (SPECT) 
Fig. 1.6: Production of [
18
F]fluoride from [
18
O]H2O in a cyclotron 
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and positron emission tomography (PET). All nuclear methods make use of 
radioactively labelled compounds that are administered (mostly intravenously) to 
the patient, so-called radiopharmaceuticals. 
1.4.1 Radiopharmaceuticals 
Radiopharmaceuticals are composed of a ligand, a chemical structure 
determining its affinity to a target structure in the human body, and one or more 
unstable atoms linked to the ligand. They are used either for diagnostic imaging 
or for endoradiotherapy in nuclear medicine. 
A radiopharmaceutical is applied to the patient through injection, distributes 
throughout the body and accumulates in its target tissue or organ.  
The distribution of the emitted radioactivity in the body can be detected by a 
scanner and transformed into an image of the examined region using various 
techniques. The radiation released during the decay of the radioactive atom can 
be used for diagnostic or therapeutic purposes, depending on the physical 
properties of the used radionuclide. (e.g. half-life and energetic characteristics of 
the emitted radiation) 
Radionuclides used for diagnostic purposes are γ emitters in scintigraphy and 
SPECT or, due to their annihilation into γ photons, β+ emitters in PET. The 
diagnostic value of γ emitters is their minor interaction and long range in tissue, 
which makes this type of radiation detectable outside the body. 
Radiopharmaceuticals used for endoradiotherapy are meant to specifically target 
and irradiate malignant tissue in order to destroy it. For this purpose, nuclides 
emitting radiation with a high grade of tissue interaction, like α, β- or Auger 
electron emitters are coupled to a ligand providing affinity to the tumor tissue. 
Depending on the size and localization of the tumor, nuclides with different 
maximum energies and ranges can be used. A selection of therapeutically used 
nuclides is presented in Table 1.1. 
  
 12 
 
Nuclide Half-life Decay Mode Max. Energy Max. Range 
68Ga 3.3d EC  <0.1MeV <10nm 
211At 7.2h α, EC 6.8MeV 65µm 
177Lu 6.7d β-, γ 0.5MeV 1.5mm 
90Y 2,7d 100% β- 2.3MeV 12mm 
Table 1.1: Therapeutically used radionuclides (data from [18]) 
1.4.2 Scintigraphy and SPECT  
Radiopharmaceuticals used in scintigraphy contain γ emitting nuclides such as 
99mTc or 131I. The radiation emitted by the radiotracer is detected by a γ camera. 
This device contains an array of scintillation crystals which emit flashes of light 
when hit by γ rays. The emitted flashes are detected by photomultiplier tubes and 
the number of counts is summed up by a connected computer system. 
Based on the collected data a two-dimensional image of the spatial count density 
is computed, in which different shades of color represent different amounts of 
detected counts. This diagram represents the distribution of the radiotracer 
concentration in the examined area.  
SPECT is very similiar to scintigraphy. The major difference is that the γ camera 
rotates around the patient. It collects sectional images which are later 
transformed into a three-dimensional model of the examined area. In Fig. 1.7, the 
result of a thyroid scintigraphy (a scintigram) using [99mTc]TcO4
- is shown. 
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Fig. 1.7: Thyroid scintigraphy showing struma (from [19]) 
1.5 Positron emission tomography 
In contrast to scintigraphy and SPECT, PET relies on the detection of γ photons 
generated through positron annihilation. The result of this measurement over 
time is a quantitative representation of the distribution of radioactivity in the 
observed tissue or organ. 
Since only coinciding γ photons are detected, annihilation events can be 
assigned to a unique spatial position in the observed area, making PET image 
resolution superior to that of other nuclear imaging techniques. 
1.5.1 Functionality of a PET scanner 
The basis for PET imaging is the detection of γ quanta formed during positron 
annihilation. A positron emitted by the radiopharmaceutical loses its kinetic 
energy through ionizations and excitation of atoms along its pathway until it 
reaches thermal velocities and combines with an orbital electron. [20] The 
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masses of the two particles are converted into γ photons, each of 511keV 
energy. These photons are emitted at an angle of almost exactly 180 degrees, 
although deviations have been reported. [7] 
Taking into account the four most important PET nuclides (i.e. Carbon-11, 
Nitrogen-13, Gallium-68 and Fluorine-18), a positron covers a distance of 
maximum 8mm before annihilation. Therefore, the spatial resolution of PET is 
limited to the maximum range of the respective nuclide. 
1.5.2 Detection of positron annihilation in PET 
The mode of positron annihilation detection is a unique advantage of PET in 
comparison to other nuclear imaging techniques. Since two photons are emitted 
simultaneously at an angle of 180 degrees, they should (if originating from the 
same annihilation event) arrive almost at the same time at the two opposed 
detectors. 
Only if both opposed detectors are activated in a small frame of time, a 
coincidence is registered. It is however possible that independent γ photons are 
falsely recognized as coincidences. In Table 1.2, three types of coincidences are 
distinguished. Two of them (“scatters” and “randoms”) may lead to the false 
assignment of a line of response (LOR), decreasing image quality. These three 
types of coincidences are depicted graphically in Fig 1.8. 
Type of coincidence Description 
true the detected photons originate from a pair annihilation 
event, the assigned LOR (line of response) is correct. 
scatter a photon has undergone scattering, but both photons 
arrive at opposed detectors at the same time, which 
results in an incorrect LOR. 
random two photons from different events are detected in 
opposed detectors simultaneously. The assigned LOR 
is incorrect. 
Table 1.2: Consequences of positron scattering for PET image reconstruction 
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Fig. 1.8: Types of coincidences in PET (from [21]) 
Another factor for decreased image quality is tissue attenuation. To register an 
annihilation event correctly, both photons must leave the body unattenuated. 
Since photons originating from deeper body compartments have to traverse body 
tissue, these photons are far more likely attenuated on their way through the 
body. In opposite, events from the outer layers of the body are far less likely 
attenuated, which results in above-average count-rates for events originating in 
outer body layers. 
This problem can be solved through attenuation correction. An additional scan is 
performed with a radiation source along all possible LORs [21] to obtain 
attenuation data of the examined region. The attenuation data can be applied to 
the uncorrected image to receive correct count densities. 
1.5.3 Radionuclides used in PET radiopharmaceuticals 
All radionuclides used in PET radiopharmaceuticals are neutron-deficient 
positron emitters. Properties of the most frequently used nuclides are shown in 
Table 1.3. 
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Nuclide Half-life (min) Decay mode Particle energy 
C-11 20.38 β+ 0.960 MeV 
N-13 9.96 β+ 1.19 MeV 
Ga-68 67.62 β+ / γ 1.83 /1.077 MeV 
F-18 109.8 β+ 0.635 MeV 
Table 1.3: The four most important PET nuclides and their characteristics (data from 
[22],[23]) 
Carbon-11 can be used to isotopically label a compound. Since carbon occurs in 
every organic molecule, carbon-12 can be exchanged for carbon-11 without 
affecting the physicochemical parameters and biological behaviour of the 
molecule.  
Due to their very short half lifes, the use of nitrogen-13 and oxygen-15 is 
restricted to very basic synthetic procedures. Since blood flow is a “fast process” 
in contrast to metabolism or receptor equilibrium processes, the short half-lifes of 
oxygen-15 and nitrogen-13 are sufficient to perform blood perfusion 
measurements of the brain and the myocardium.  
Fluorine-18 is a very common nuclide in radiochemistry. Its half-life of 109.8 
minutes allows its use in multi-step syntheses, the observation of slowly 
equilibrating processes, and its shipping to satellite medical facilities.[24]  
Its maximum positron energy of 0.635 MeV results in a comparatively low 
radiation burden for the patient and a maximum range of 2.4mm in the human 
body. [22] For this reason, the spatial resolution of PET scans using a 
[18F]fluorine-labelled radiotracer is superior to scans performed with other 
radionuclides. 
Another advantage of a [18F]fluorine label is that its atom radius is very similar to 
that of a hydrogen atom. [25] Therefore, a hydrogen atom can be substituted with 
[18F]fluorine without much steric alteration of the molecule.  
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The only downside to fluorine-18 radiolabeling is the high electronegativity of 
fluorine, which can drastically influence the physicochemical parameters and 
biological behaviour of a molecule in comparison to its unlabelled counterpart. 
1.6 Radiofluorination methods 
Various approaches for the introduction of a fluorine-18 radiolabel into a lead 
structure are known. Electron-rich reactants such as carbon-carbon double 
bonds, aromatic rings or carbanions can be labelled using electrophilic 
fluorination methods. Nucleophilic fluorination can be applied to electron-poor 
reactants such as substituted alkanes or aromatic structures with electron-
drawing substituents.  
1.6.1 Electrophilic fluorination 
The source of fluorine for electrophilic fluorinations is [18F]fluorine ([18F]F2) gas. It 
can be produced either by the 20Ne (d, α) 18F or 18O (p,n)18F reaction in a 
cyclotron. Milder, less reactive radiofluorination agents derived from [18F]F2 gas 
are acetylhypofluorite [18F]CH3COOF and xenon difluoride [
18F]XeF2. [26, 27] 
[18F]F2 cannot be produced carrier-free, since “cold” [
19F]F2 gas needs to be 
introduced into the cyclotron target to remove 18F adsorbed onto the target wall 
and to enable the formation of 18F-19F molecules. In this step, the radiofluorine 
adsorbed onto the target wall is recovered and an isotopic exchange takes place: 
a fluorine atom of [19F]F2 is exchanged for a fluorine-18 atom.  
For this reason, every [18F]F2 molecule contains a 
19F atom. Theoretical specific 
acitivity is thus reduced to 50%. [17, 28] 
Because of its high reactivity, the (regio-)selectivity of [18F]fluorine is low. 
Formation of undesired side-products is regularly observed and makes extensive 
purification necessary. Often protective groups have to be introduced to protect 
reactive moieties, demanding further de-protection steps following the actual 
radiofluorination. [29] 
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Because of the disadvantageous properties of [18F]fluorine and its derivatives, 
electrophilic fluorinations are used only if a simple nucleophilic route is not 
available and high specific activities are not necessary: e.g. when analogues of 
endogenous compounds present in the body in high concentrations – i.e. labelled 
sugars, amino acids or fatty acids [30] are used. 
1.6.2 Nucleophilic fluorination 
Nucleophilic substitution is performed using [18F]fluoride as the fluorine source. It 
is available through the 18O (p, n) 18F reaction directly from the cyclotron. No-
carrier-added (n.c.a.) [18F]fluoride in high specific acivities is a mandatory 
prerequisite for the investigation of low-density receptor sites. 
However, since [18F]fluoride is obtained in an aqueous solution, it is highly 
hydrated and thus inactivated for nucleophilic substitution reactions. To activate 
[18F]fluoride, it must be separated from its aqueous solution by means of an 
anion exchange resin and then transferred to the organic phase using a phase 
transfer catalysator. 
Trace water is removed by azeotropic distillation with acetonitrile. This method is 
described in chapters 2.2.2. and 2.2.3. Since [18F]fluoride is easily protonated to 
form [18F]hydrofluoric acid ([18F]HF), the reaction medium is basified to prevent 
protonation, which would make [18F]fluoride unavailable for nucleophilic 
reactions. Nucleophilic substitution reactions take place in polar but aprotic 
solvents like acetonitrile, dimethyl sulfoxide (DMSO) or dimethyl formamide 
(DMF). 
In terms of reaction mechanism, substitutions with [18F]fluoride are displacement 
reactions of electron-drawing leaving groups like halides, tosylates, mesylates or 
triflate groups following a SN2 mechanism. 
 
An example for this type of reaction is the production of 2-[18F]fluoro-2-deoxy-D-
glucose ([18F]FDG) from a fully acetylated mannose triflate precursor (1,3,4,6-
tetra-O-acetyl-2-tnifluormethanesulfonyl-β-D-mannopyranose). [31] The triflate 
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group is displaced by the [18F]fluoride ion. Subsequently, the protected hydroxy 
groups are de-protected by hydrolysis using acid or base, yielding [18F]FDG. A 
scheme of this reaction is shown in Fig. 1.9. 
 
 
Fig. 1.9: Synthesis of [
18
F]FDG from an acetylated mannose triflate precursor (from [24]) 
Nucleophilic fluorination of arenes is of great importance in the development of 
fluorine-18 labelled radiotracers because of the good metabolic stability of 
substituted aromatic compounds. [32] 
To make arenes accessible to nucleophilic substitution reactions, they need to be 
activated by electron-drawing substituents in ortho- or para- position relative to 
the leaving group. Suitable leaving groups are nitro, cyano, carbonyl and 
especially trimethylammonium groups. 
An example for this type of reaction is the one-step synthesis of [18F]Altanserine 
from its para-substituted nitro-precursor and is shown in Fig.1.10. 
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1.7 Microfluidics in PET chemistry 
Microfluidic chemistry is an approach to scale down chemical reactions from the 
mL to the µL range. Chemical synthesis on the micro-scale offers several 
advantages compared to conventional vessel-based chemistry. Since fluids in 
microstructures flow without turbulence, mixing can occur by diffusion only. The 
diffusional mixing resulting from laminar flow is very rapid. [33] The use of very 
small reaction volumes in the µL-range allows the usage of small amounts of 
precursor and radioactivity, leading to decreased formation of side products and 
reduced costs. 
Since lower amounts of radioactivity are used, the radiation exposure of the 
operator is minimized. Another advantage of microfluidic systems is that most 
systems can be operated at high pressures (up to 400psi in the case of the 
Advion NanoTek LF ® system) so solvents can be used way above their boiling 
points at normal pressure. This enables the use of very high reaction 
temperatures impossible in vessel-based chemistry because of solvent 
evaporation occuring at room pressure. 
The numerous advantages of microfluidic chemistry systems lead to higher 
incorporation yields, possibly lower amounts of side products and thus easier 
Fig. 1.10: Synthesis of [
18
F]Altanserine in a one-step reaction (from [24]) 
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product purification. It might even enable reactions that would not be possible 
under conventional radiolabelling conditions. 
1.7.1 The Advion NanoTek LF 
This integrated synthesis apparatus consists of a liquid flow (LF) reaction unit 
containing three microsyringe pumps for solvent / reagent transport and a reactor 
heater capable of holding up to four reactors. The coin-shaped microreactors are 
made of fused silica tubing held in a brass ring, which is filled with a 
thermoresistant polymer to hold the tubing in place. 
All components of the system are accessed and controlled through a dedicated 
software interface. Reaction conditions (flow speed, reaction temperature, 
amounts of precursor and radioactivity used, time of residence in the reactor) 
were adjusted through this interface. All steps of the synthesis could be 
automated by using the proprietary programming language of the system.  
It is also planned to connect the system to analytical instruments (e.g. HPLC 
and/or mass spectrometry) to constantly monitor the quality of the synthesized 
product and accordingly adjust reaction parameters.  
The system is shown in Fig.1.11 with the liquid flow reaction module making up 
the biggest part of the system. The concentrator unit is shown in the far right of 
the picture. A more detailed schematic of the system set-up is shown in Fig. 2.4. 
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Fig. 1.11: The Advion NanoTek microfluidic chemistry system (from [34]) 
1.8 Dopamine 
Dopamine (2-(3,4-Dihydroxyphenyl)ethylamine) is a biogenic amine of the group 
of catecholamines (derivatives of 1,2-dihydroxybenzene). It is biochemically 
synthesized from L-tyrosine. It was long thought to be only a precursor to 
epinephrine and norepinephrine, until Carlsson et al. discovered that dopamine is 
a neurotransmitter of its own in 1958. [35] 
In the experiment leading to this discovery, male rabbits were injected with 
reserpine (an indole alkaloid from the roots of Rauvolfia serpentina that inhibits 
the vesicular monoamine transporter (VMAT-2) for 5-hydroxytryptamine (5-HT), 
dopamine (DA), epinephrine (E) and norepinephrine (NE). [36]  
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The result of reserpine treatment was a total depletion of catecholamines in the 
adrenal medullary as well as in other tissues, including the brain. The reserpine-
treated animals were immobilized and sedated. (see Fig. 1.12)  
 
Fig. 1.12: Effects of L-DOPA on rabbits treated with reserpine (upper picture: reserpine-
treated rabbits, lower picture: rabbits treated with L-DOPA following reserpine injection  
(from [37])) 
 
Several hours after the injection of reserpine, the animals were treated with L-
DOPA (the precursor of dopamine). 15 minutes after the L-DOPA injection the 
animals were “instantaneously restored to full mobility and wakefulness by 
repletion of dopamine”. [35] When the researchers examined the brains of the 
animals, they found them still fully depleted of NE, but replenished of DA. Their 
conclusion was that dopamine must have restored the awareness and motor 
abilities of the reserpine-treated animals back to normal. [35] 
This finding led the researchers to the assumption that dopamine plays a role 
other than that of a precursor to norepinephrine in brain physiology. This theory 
was even more strengthened by experiments indicating evidence of a “dopamine 
receptor” by Kebabian et al. in 1972 [38], leading to the discovery of the 
dopamine receptor subtypes D1 and D2 in 1979. [39] Further research in the 
1980s revealed even more dopamine receptor subtypes. 
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1.8.1 Dopamine in human physiology  
Dopamine plays an important role in many bodily functions. It is involved in the 
control of movement, motivation and cognition. [40] It is also considered a key 
substance in the development of reward-seeking behaviour. [41] 
Dysfunctions of the dopaminergic system have implications in several neurologic 
and psychiatric diseases. Parkinson‟s disease, Chorea Huntington, schizophrenia 
and attention deficit hyperactivity disorder (ADHD) are the most prominent 
disorders linked to malfunctions of the dopaminergic system. [42] 
1.8.1.1 Dopamine receptors  
The physiological actions of dopamine are mediated through dopamine 
receptors. Structurally, all dopamine receptors consist of 7 transmembrane 
spanning helices, which can be divided into extracellular and intracellular 
sections. Dopamine binds to its extracellular binding pocket and initiates a 
conformational change of the receptor and a subsequent activation of the 
corresponding G-protein. 
Based on sequence homology and pharmacology, dopamine receptors can be 
classified into two sub-families: the D1-like receptors (D1A-1D and D5) and D2-like 
receptors (D2,3,4). [43] Receptors of the D1-like family couple to Gs proteins which 
increase the activity of the adenylyl cyclase upon activation. Dopamine D2-like 
receptors couple to Gi proteins which inhibit the activity of the adenylyl cyclase.  
The modification of adenylyl cyclase activity through dopamine receptor 
activation leads to a change in the level of the second messenger cAMP (3„,5„-
cyclic adenosine monophosphate) and ultimately sets off a physiological 
response. 
1.8.1.2 Dopaminergic pathways in the human brain 
There are four major dopaminergic pathways in the central nervous system: the 
nigro-striatal, mesolimbic, mesocortical pathways and the tiberoinfundibular 
pathway. [44]  
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The axons of the nigro-striatal dopamine pathway project from the substantia 
nigra to the striatum. The nigro-striatal pathway is essential for motor regulation. 
When neurons in this pathway degenerate, symptoms of Parkinson‟s disease 
(tremor, rigidity and bradykinesia) develop.  
The cell bodies of the mesolimbic and mesocortical dopamine pathway are 
located in the ventral tegmental area of the midbrain. They connect the ventral 
tegmental area to the limbic system, respectively the cortex. 
The neurons of the mesolimbic dopamine pathway are activated when joy or 
desire are felt. [45] The behaviours connected with their activation are thereby 
reinforced. It has been shown that drugs of abuse promote dopamine release in 
the mesolimbic dopamine pathway. [45]  
Lastly, the neurons of the tuberoinfundibular dopamine pathway project from the 
hypothalamus to the pituitary gland, where dopamine is involved in the regulation 
of prolactine secretion. [46] 
1.8.1.3 Pathophysiology of the dopaminergic system 
Abnormal dopaminergic transmission is present in several disorders of the CNS. 
The most prominent is Parkinson‟s disease. In Parkinson‟s, the degeneration of 
dopaminergic neurons in the nigro-striatal pathway causes the typical symptoms 
of this disease: tremor, rigidity and bradykinesia, as well as cognitive impairment. 
[47] 
Another disease with impaired dopaminergic transmission is schizophrenia. 
Involvement of dopamine in schizophrenia has been first suggested by Van 
Rossum in 1967 in his dopamine hypothesis of schizophrenia. [48] 
This theory was confirmed by Seeman et al. in 1975 in an experiment that 
verified that haloperidol, an antipsychotic, and dopamine bind to the same site in 
the brain, which was later found to be the dopamine D2 receptor. [49] Through 
this discovery the involvement of the dopaminergic system in schizophrenia had 
clearly been proven. 
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Lastly, it has also been shown that the mesolimbic dopamine system plays an 
important role in the development of substance addiction. [41] 
1.8.2 Imaging of the dopaminergic system 
It is essential to have suitable radiotracers to study the role of the dopaminergic 
system in addiction, schizophrenia, Parkinson‟s disease and other diseases of 
the central nervous system. Several radiotracers, utilizing various types of 
radiolabels (99mTc, 123I, 11C and 18F) have become available to study the 
components of the dopaminergic system using SPECT and PET imaging 
techniques. The targets of these radiotracers in the dopaminergic synapse are 
shown in Fig. 1.13 below. 
 
Fig. 1.13: Biochemistry of the dopaminergic synapse (from [50]) 
 27 
 
1.8.2.1 Imaging of the dopaminergic presynapse 
The presynaptic components of the dopaminergic synapse include the dopamine 
reuptake transporter (DAT), enzymes of dopamine synthesis (DOPA 
decarboxylase), metabolism (MAO A, B) and the vesicular monoamine 
transporter (VMAT-2). A selection of radiotracers for SPECT and PET targeting 
these structures is shown in Table 1.4. 
Since the abovementioned structures are unique to dopaminergic neurons, the 
binding of radiotracers strongly correlates with the number of intact dopaminergic 
neurons. Therefore, they can be used to estimate the number of remaining 
functional dopaminergic neurons in diseases of the basal ganglia. [51]  
Dopamine synthesis and storage can be evaluated using 6-[18F]fluoro-L-DOPA 
(FDOPA), which is actively transported across the blood brain barrier by an 
amino acid carrier, decarboxylated to [18F]fluorodopamine and stored in vesicles 
analogously to endogenous dopamine. [52]  The presynaptic dopamine reuptake 
transporter (DAT) can be targeted by radiotracers structurally similar to the DAT 
inhibitor (-)-Cocaine. The DAT is an important target in the diagnosis of early 
stage Parkinson‟s disease when no motor signs are present yet, since binding to 
this transporter is a marker for the number of intact nigro-striatal dopaminergic 
Target Name of tracer 
Dopamine synthesis, storage [18F]FDOPA, [11C]DOPA 
Dopamine reuptake transporter (DAT) [11C]Nomifensin, [11C]WIN, 
[99mTc]TRODAT, [123I]β-CIT, [123I]FP-
CIT] 
Vesicular monoamine transporter 
(VMAT-2) 
[11C]DTBZ 
MAO B [11C]Deprenyl 
Table 1.4: Tracer targets in the dopaminergic presynapse 
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neurons. [53] A study has shown that decreased binding of [123I]β-CIT to striatal 
DAT correlates to the severity of symptoms of the disease. [54]  
As a further parameter of dopaminergic synapse function, the synaptic dopamine 
degradation rate by monoamine oxidase B (MAO B) can be assessed using a 
carbon-11-labelled MAO B inhibitor, [11C]Deprenyl. [55] 
1.8.2.2 Imaging of dopamine receptors 
Dopamine receptors are present on both sides of the dopaminergic synapse 
(depicted in Fig.1.13). On the presynaptic side dopaminergic auto-receptors 
modulate the synthesis and release of dopamine while they function in cell-to-cell 
communication on the postsynaptic side. [56] 
The first carbon-11-labelled dopamine D1 antagonist was [
11C]SCH23390, a 
benzazepine derivative. It has been used to study the influence of age on 
dopamine D1 receptor binding potentials. [57] Also, [
11C]SCH23390 has been 
used to assess the D1 receptor occupancies in patients treated with a variety of 
antipsychotic drugs in order to investigate their sites of action [58].  
Other uses of [11C]SCH23390 were the assessment of D1 receptor densities as a 
marker of brain degeneration in Huntington‟s disease [59, 60] and Parkinson‟s 
disease. [61] 
Another dopamine D1 receptor ligand possessing more favourable binding 
properties than [11C]SCH23390 is [11C]NNC112, also a benzazepine derivative. It 
shows lower accumulation in the cerebellum and higher affinity to dopamine D1 
receptors than [11C]SCH23390. [62] 
The synthesis of fluorinated benzazepine derivatives targeting the dopamine D1 
receptor has been described by Yang et al in [63]. This study has shown that the 
nitrogen atom of the azepine ring in substituted benzazepines cannot 
accommodate substituents larger than methyl without a significant loss of binding 
affinity.[63] Therefore, fluoroalkylations are not possible in this position. However, 
bulky substituents can be tolerated in the phenyl ring in all positions without a 
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significant loss of binding affinity. [64] A fluorinated benzazepine D1 receptor 
tracer is shown among two carbon-11 labelled benzazepines in Fig. 1.14. 
 
Fig. 1.14: Structures of 
11
C and 
18
F- labelled dopamine D1 receptor tracers (from [63]) 
The dopamine D2 receptor is the main target for classic neuroleptics. Therefore, 
several dopamine D2 receptor radiotracers have been used to assess the 
relationship between D2 receptor occupancy and therapeutic efficacy of 
neuroleptics. [65] 
The lead structure for dopamine D2 receptors are the substituted benzamides. 
First-generation benzamide radiotracers, [11C]Raclopride and [123I]IBZM, 
exhibited only moderate affinities for the D2 receptor. For this reason, imaging of 
D2 receptors was possible only in a brain area with very high dopamine D2 
receptor density, namely the striatum. 
Recently developed high-affinity D2 receptor tracers such as [
11C]FLB457 and 
[18F]Fallypride allow the imaging of dopamine D2 receptors also in extrastriatal 
brain areas, where the concentration of D2 receptors can be up to two orders of 
magnitude lower than in the striatum. [66] 
With these ligands, the binding of antipsychotic drugs to extrastriatal D2 receptors 
can be investigated and new insights into the role of these receptors in 
neuropsychiatric disorders can be gained. [67] 
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1.8.2.3 Imaging of dopamine D2 receptors using [
18F]Fallypride 
Mukherjee et al. developed the dopamine D2 tracer [
18F]FPMB in 1990. Because 
of its moderate lipophilicity (log Kw = 1.64), the brain uptake of [
18F]FPMB in 
cebus monkeys was limited to 0.06% per injected dose. [68] 
For this reason, the N-ethyl group in [18F]FPMB was substituted for a N-allyl 
group, leading to the compound [18F]Fallypride. This compound showed 
improved lipophilicity (log Kw = 2.43) and brain uptake (0.10% per injected dose). 
Also, an increased affinity for D2-like receptors (Ki = 0.03nM for [
18F]Fallypride 
versus Ki = 0.26nM for [
18F]FPMB) [69] has been observed. 
 
Fig. 1.15: Structures of the dopamine D2 receptor tracers [
18
F]FPMB and [
18
F]Fallypride 
Biodistribution studies in rats have shown rapid clearance of [18F]Fallypride from 
unspecific binding sites like cerebellum and frontal cortex and preferential binding 
of [18F]Fallypride to striatal receptors. A striata-to-cerebellum rate of 122 was 
observed 2 hours post-injection [69], which is higher than previously observed 
with fluorine-18-labelled substituted benzamides and salicylamides [70]  
[18F]Fallypride has been used to assess dopamine D2/3 receptor distribution in 
humans, showing accumulation of radioactivity in striatal and extrastriatal 
regions. [71]  
Another interesting study conducted with [18F]Fallypride was the measurement of 
dopamine release mediated by d-amphetamine. Riccardi et al. found a significant 
decrease in [18F]Fallypride binding potentials in various brain regions, indicating 
amphetamine-mediated stimulation of dopamine release in these regions. [72] 
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[18F]Fallypride has also been used to quantify dopamine D2 receptor occupation 
by the atypical antipsychotic clozapine in schizophrenic patients. This 
examination by Grunder et al. showed that clozapine primarily binds to 
extrastriatal D2 receptors in the cortex, which may explain the lower incidence of 
extrapyramidal symptoms in the class of atypical neuroleptics, to which clozapine 
belongs. [73] 
The comparison of receptor binding potentials in healthy volunteers and 
clozapine-treated schizophrenics can be seen in Fig. 1.16.  
In summary, [18F]Fallypride has several advantages in comparison to older 
dopamine D2 receptor tracers, including its increased lipophilicity and higher 
affinity to dopamine D2-like receptors. These improved characteristics allow the 
visualization of dopamine D2-like receptors in brain areas with low dopamine D2-
like receptor densities. 
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Fig. 1.16: Mean binding potentials of dopamine D2-like receptors in healthy volunteers (top 
row) and clozapine-treated schizophrenics (middle row), measured with [
18
F]Fallypride 
PET. The D2/D3 receptor occupancy distribution is shown in the bottom row. (from [73]) 
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2 Materials and methods 
2.1 Materials 
All chemicals were used as bought if not stated otherwise. 
2.1.1 Synthesis chemicals 
 Precursor: (S)-2,3-dimethoxy-5-[3-[[(4-methylphenyl)-sulfonyl]oxy]-propyl]-
N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]benzamide was purchased from 
ABX-Advanced Biochemical Compounds. (Dresden, Germany) 
 Reference standard: 5-(3-fluoropropyl)-2,3-dimethoxy-N-[[(2S)-1-(2-
propenyl)-2-pyrrolidinyl]methyl]benzamide was purchased from ABX-
Advanced Biochemical Compounds. 
2.1.2 Solvents, buffers 
 Acetonitrile and ammonium formate were bought from Merck (Darmstadt, 
Germany). 
2.1.3 TLC and HPLC equipment 
 Analytical thin layer chromatography (TLC) was performed on Silicagel 
RP-18 60 F254 plates from Merck. 
 HPLC analyses were performed on a Merck LiChrospher 100-250 RP-18e 
column (5µm, 250mm x 4.6mm) using a Merck-Hitachi LaChrom gradient 
system being comprised of a L-6200 gradient pump, a Merck-Hitachi L-
7400 UV detector set to a wavelength of 254nm and a lead-shielded NaI 
radiodetector by Berthold Technologies.(Bad Wildbad, Germany) 
 Autoradiographic analyses of TLC plates were performed on an 
InstantImager apparatus from Packard Instrument Company.(Meriden, 
USA) 
2.1.4 Cyclotron equipment 
 [18F]Fluoride was produced using the 18O(p, n)18F nuclear reaction in a GE 
PETtrace cyclotron (16.5 MeV protons).  
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 Enriched H2
18O was bought from Rotem Medical.(Dimona, Israel) 
2.1.5 Phase transfer of [18F]Fluoride 
 Kryptofix 2.2.2. (4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]-
hexacosane) and K2CO3 were bought from Merck. 
 Elution of [18F] was accomplished using Chromafix® 30 PS-HCO3 
cartridges (Macherey-Nagel, Düren, Germany). 
2.1.6 Vessel based synthesis 
 Vessel based syntheses were performed in 1mL Grad V-Vials with 13-425 
S/T Caps from Wheaton Science Products. (Millville, USA) 
 Vials were sealed with PTFE silicone septa from Wheaton Science 
Products. 
2.1.7 Microfluidic synthesis apparatus 
 Microfluidic syntheses were performed on a NanoTek LF Microfluidic 
synthesis apparatus from Advion BioSystems. (Ithaca, USA) 
 Azeotropic drying for the microfluidic syntheses was performed in the 
NanoTek CE Unit from Advion BioSystems. 
 The system was operated using a Laptop computer with the NanoTek LF 
3.2 software installed. 
2.2 Methods 
2.2.1 Production of [18F] F- in the GE PETtrace cyclotron 
[18F]fluoride was produced by irradiation of [18O]water (>98%) with a proton 
beam, utilizing the 18O (p, n)18F nuclear reaction in a silver target. 
The irradiation process and product delivery were controlled by a computer 
module. When the desired activity level was reached, irradiation was stopped 
and the product was delivered into a V-vial situated in a lead-shielded hot cell. 
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Because the [18F]fluoride was delivered in a solution of [18O]water, further steps 
were necessary to make it available for nucleophilic substitution reactions in 
organic solvents. 
2.2.2 Complexation, phase transfer and azeotropic drying of [18F]Fluoride 
The removal of bulk [18O]water was achieved by passing the aqueous 
[18F]fluoride solution through an anion exchange cartridge. The [18F]fluoride was 
thereby retained on the cartridge while the [18O]water was collected seperately. 
Subsequently, the cartridge was eluted with 1mL of a solution of potassium 
carbonate (4.5mg, 32.6µmol) and the cryptand Kryptofix 2.2.2. (20mg, 53.2µmol) 
in acetonitrile / water (70:30 v/v%).  
The potassium cation is complexed by the aminopolyether Kryptofix 2.2.2. As the 
counter-ion of the complexed K+, [18F]fluoride is dragged into the organic phase 
together with the potassium-Kryptofix 2.2.2. complex, leaving a highly activated 
[18F]fluoride ion. 
 
Fig. 2.1: Complexation and phase transfer of [
18
F]fluoride (from [74]) 
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To ensure sufficient nucleophilicity for nucleophilic substitution reactions, 
[18F]fluoride had to be stripped of hydrate water (up to 15 [18O]water molecules 
can surround a fully hydrated 18F- ion). [75] 
Water and acetonitrile form a minimum boiling point azeotrope (83.7% 
acetonitrile (w/w)) boiling at 76.5°C at atmospheric pressure [76]. For this reason, 
water can be easily removed by evaporating the solution to dryness. 
Thus, the solution was heated to 100°C and trace water was azeotropically 
removed by adding 3 portions of acetonitrile (each 250µL) over a course of 15 
minutes. This process was carried out under a stream of nitrogen gas. 
The dried [18F]fluoride was then dissolved in anhydrous acetonitrile and 
transferred to the reaction vessels. 
2.2.3 Synthetic route 
The synthesis of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-
dimethoxybenzamide, abbreviated [18F]Fallypride, started from the precursor 
substance (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-tosyloxypropyl)-2,3-
dimethoxybenzamide, abbreviated tosyl-Fallypride. It was carried out as a one-
step synthesis by adding a solution of the [18F]fluoride-K2.2.2-K+-complex to the 
precursor solution. The solvent in both synthesis techniques was acetonitrile. 
The mechanism for the introduction of the radiolabel was the nucleophilic 
substitution of the toluenesulfonic acid group in the precursor substance by 
[18F]fluoride. 
This reaction yields [18F]Fallypride and the resonance-stabilized toluenesulfonic 
acid anion as the leaving group. Since the negative charge is delocalized 
throughout the leaving molecule, it makes an excellent leaving group by not 
competing as a nucleophile with [18F]fluoride. A schematic of the reaction is 
depicted in Fig. 2.2. 
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Fig. 2.2: Synthetic route of the radiofluorination of tosyl-Fallypride 
2.2.4 Vessel-based synthesis of [18F]Fallypride 
Vessel-based synthesis of [18F]Fallypride was carried out by adding a solution of 
the dry n.c.a. [18F]fluoride-K2.2.2-K+-complex to a solution of tosyl-Fallypride 
dissolved in acetonitrile. The reaction took place in 1mL V-Vials which were 
sealed with septa and then placed in an aluminum heating block for the specified 
period of time. Immediately after completion, reaction mixtures were analyzed for 
determination of radiochemical incorporation yields and impurities using radio-
TLC and radio-HPLC. 
The influence of reaction temperature on synthesis yields was tested at 40°C, 
60°C, 70°C, 80°C and 85°C using a fixed precursor concentration of 5mg/mL and 
a fixed reaction duration of 15 minutes. Since these reactions were carried out 
under room pressure, higher temperatures could not be evaluated because of the 
boiling point of the solvent acetonitrile. 
The influence of precursor concentration and reaction duration on reaction yields 
was evaluated. Precursor concentrations used were 1mg/mL, 2.5mg/mL and 
5mg/mL. These experiments were carried out at varying reaction times of 2, 5, 15 
and 30 minutes while the reaction temperature was held constant at 70°C. 
 38 
 
2.2.5  Microfluidic synthesis of [18F]Fallypride 
The microfluidic synthesis of [18F]Fallypride was carried out using the Advion 
NanoTek LF microfluidic synthesis apparatus as described in chapter 1.7.1. A 
detailed schematic of the system set-up is presented in Fig 2.3. 
 
Fig. 2.3: Schematic illustration of the set-up of the Advion NanoTek LF system (from[77]) 
Before a series of experiments was started, all components of the system were 
flushed with purified water and acetonitrile in order to remove any potential 
contaminations present in the system. Cleaning runs were fully automated by 
using a macro written in the proprietary programming language of the Advion 
NanoTek LF system. The source code of the master cleaning routine for reagent 
lines, solvent and waste lines, storage loops, magnetic valves and the 
microreactor is shown in Fig. 2.4. 
Fig. 2.4: Commented source code of the master cleaning routine for the Advion NanoTek 
LF system. 
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After the initial cleaning run, the preparation of [18F]fluoride from target water 
started. Also for this process, a macro was programmed to fully automate the 
separation and azeotropic drying of [18F]fluoride. (see Fig. 2.5) 
The [18F]fluoride anion was separated from the solution of [18O]water by trapping 
it on an anion exchange cartridge (PS-HCO3) and subsequent elution from the 
cartridge with a solution of Kryptofix 2.2.2 (20mg, 53.2µmol) and potassium 
carbonate (4.5mg, 32.6 µmol) in acetonitrile/water (70:30 v/v%). Removal of 
residual water was performed by azeotropic drying of the resulting solution. 
In the drying process, 500µL acetonitrile from the pump of the CE unit and two 
200µL portions from pump 3 of the LF unit were added over a course of 15 
minutes. After completion of the drying process, the dried [18F]fluoride was re-
solved in 500µL acetonitrile. 
Time delay Pump Action Comment 
0 Wait 
Batch FDG: SBFDG_v35; Plumbing: SBFDGv2_1 ; 
 3-Channel Reactor; 500 uL run, ;N2 Flow set to 1.5 scfh 
0 /3o8V4000A48000R P3 : fill syringe 
0 L3702000100004DL3602000300004E Heat concentrator 1 up to 100 C 
1000 /5go1V3200A12000M2000o5V1200A0M500G3go6V6400A12000M1000o1A0G4R CE: Load Target Water 
120000 /7U2M5000U1M5000u2R G: Turn on Nitrogen 
20000 /5o2V2400A6000o5V2400A0R CE: add 0,5mL K222 
10000 /5o3V2000A6000M2000o5V75D4800o6V75D1200o2V2000A0R CE: Add 0.5 mL MeCN 
10000 L3702000110004EL3602000300004E Heat concentrator 1 up to 110C 
200000 /3o6V10000D9600R P3: add 200uL MeCN 
60000 /3o6V10000D9600R P3: add 200uL MeCN 
50000 L37020000260054L3602000300004E CE: Set Heater to 26oC 
300000 /7u1R G: Turn off Nitrogen 
1000 /3o6V10000D24000R P3: solve Activity in 500uL MeCN 
Fig. 2.5: Commented source code of the azeotropic drying routine for [
18
F]fluoride. 
The precursor solution containing tosyl-Fallypride and dry [18F]fluoride were then 
loaded into the storage loops of pump 1 and 3 of the LF unit. Transfer lines 1 and 
3 were filled with the respective solutions from loop 1 and 3 and the reactor was 
swept with acetonitrile via pump 3.  
After the preparatory steps described above, the system was ready to perform 
reactions. In the reaction depicted in Fig. 2.6, 30µL of dried [18F]fluoride solution 
and 30µL of precursor solution were pushed through the reactor at an overall 
flow rate of 60µL/min. The subsequent sweep 1 performed via pump 3 pushed 
the reaction mixture out of the system. The final sweep cleaned the system of 
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remaining reactands and pushed the reaction mixture into the collecting vial. The 
total reaction volume was 100µL of reaction mixture + 15.7µL for sweep 1 + 20µL 
to the distribution valve + 300µL to the collecting vial, adding up to 335.7µL of 
total reaction volume. The duration for a single experiment was 289 sec. 
 
Fig. 2.6: The course of events in a typical reaction using the discovery mode of the Advion 
NanoTek LF 
An additional tool for reaction control was the pump pressure and radiation 
graph. The system possesses three built-in pressure sensors that transmit the 
pressure status of every pump to the user interface.  
The system also comes with three radiation detectors that can be placed freely at 
any spot of the system. A radiation sensor was placed on the storage loop for the 
[18F]fluoride solution to monitor the decay of [18F]fluoride during a series of 
experiments. 
The data collected from the pressure and radiation sensors were recorded in a 
real-time graph visible in the main window of the user interface. The graph for the 
discussed reaction is shown in Fig. 2.7.  
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Fig. 2.7: Detector graph for a triplet experiment of the reaction shown in Fig. 2.6. Graphs 
P1, P2, P3 represent the pressure course of the particular pump. Rad1, Rad2, Rad3 
represent radiation detectors. 
The influence of reaction temperature and precursor concentration on synthesis 
yields was evaluated at room temperature (26°C), 100°C, 140°C, 150°C, 160°C, 
170°C and 180°C for precursor concentrations of 0.5mg/mL 1mg/mL, 2.5mg/mL 
and 5mg/mL. All reaction temperatures were evaluated in a series of experiments 
for each precursor concentration. 
2.2.6 Quality control procedures 
To ascertain the purity of the resulting [18F]Fallypride and to evaluate the 
radiochemical yields of a reaction, a quality control system was set up. A radio-
TLC system was used for the quantification of radiochemical incorporation yields 
and determination of potential side-products. The identity of the reaction products 
and side-products was evaluated using a radio-HPLC assay. 
2.2.6.1 Development of a thin layer chromatography system for the 
autoradiographic quantification of [18F]Fallypride 
To achieve sufficient separation of the reaction product from unreacted 
[18F]fluoride and side-products at short running times, several TLC systems were 
evaluated. Stationary phases used were silica gel 60 F254 and silica gel 60 RP-18 
F254S. 
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The separation of unreacted [18F]fluoride from the product was the most 
important factor for the usability of a chromatographic system. A prerequisite for 
a usable TLC system was the fixation of [18F]fluoride at the starting point of the 
TLC run. This precondition was not fulfilled by eluents containing higher amounts 
of water (eluents D, E, F, G) as these were able to solve and transport the 
[18F]fluoride ion. Details concerning the evaluation of RF values of [
18F]fluoride 
and [18F]Fallypride using the eluents listed in table 4 are presented in Table 2.2. 
Also, when silica gel 60 phases were used in combination with an eluent 
containing a high percentage of water, intense smearing of the substance over a 
wide RF range was observed. We were able to avoid smearing by using a RP-18 
stationary phase with a high percentage of non-polar solvent in the mobile phase 
instead. (eluents A, B or C)  
Best results were obtained using silica gel 60 RP-18 F254S and eluent A (95% 
acetonitrile / 5% water v/v%) because of sufficient separating capacity, concise 
peak form and short run times of this chromatographic system. 
Abbreviation Composition of the eluent 
A 95/5 MeCN / H2O (v/v%) 
B 90/10 MeCN / H2O (v/v%) 
C 80/20 MeCN / H2O (v/v%) 
D 70/30 MeCN / H2O (v/v%) 
E 60/40 MeCN/ H2O (v/v%) 
F 80/20 MeOH / H2O (v/v%) 
G 50/50 MeOH / 1M Ammonium                    
acetate buffer (v/v%) 
Table 2.1: Compositions of eluents used in radio-TLC  
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The result of a TLC separation using silica 60 RP-18 F254S plates as a stationary 
phase and eluent A as the mobile phase is presented in Fig. 2.8. The unreacted 
[18F]fluoride was retained at the starting point while [18F]Fallypride was 
transported by the eluent, leading to separation of both substances. The 
radioactive spots on the TLC strips were quantified using an InstantImager 
autoradiographer, allowing the determination of radiochemical incorporation 
yields of reactions. 
 
In Table 2.2, RF values of TLC runs with [
18F]fluoride or [18F]Fallypride using 
various combinations of mobile and stationary phases are presented. When two 
values are listed for a substance, the substance peak has been split up during 
the separation run, making the TLC system unusable for separation runs.
Fig. 2.8: Results of the separation of [
18
F]Fluoride from [
18
F]Fallypride using radio-TLC. 
[
18
F]fluoride remains at the starting point. 
 
Region 1: [18F]fluoride 
Region 2: [18F]Fallypride 
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Eluent [18F]F- in a solution of H2O (RF) Product solution (RF) 
 KGF254 RP-18 KGF254 RP-18 
A 95/5 (v/v) MeCN / H2O 0.006±0.0005 0.042±0.035 0.441±0.031 0.377±0.056 
B 90 /10 (v/v) MeCN / H2O 0.002±0.004 0.002±0.003 0.417±0.011 0.573±0.050 
C 80/20 (v/v) MeCN / H2O 0.029±0.009 0.012±0.013 0.791±0.013 0.708±0.023 
D 70/30 (v/v) MeCN / H2O 0.066±0.013 0(5.15%) / 
0.1575±0.006 
(91.7%) 
0.823±0.018 0.769±0.009 
E 60/40 (v/v) MeCN / H2O 0.038±0.061 
(5.7%) / 
0.377±0.004 
(91.10%) 
0 (2.03%) / 
0.5803±0.010 
(96.53%) 
0.834±0.039 0.848±0.066 
F 80 / 20 (v/v) MeOH / H2O 0 (8.35%) / 
0.195±0.0037 
(88.2%) 
0 (4.07%) / 
0.567±0.104 
(93.8%) 
no separation no separation 
G 50/50 (v/v) MeOH/ 1M 
Ammonium acetate buffer 
0.147±0.049 0.271±0.062 no separation no separation 
Table 2.2: Development of a TLC system for the separation of [
18
F]fluoride from [
18
F]Fallypride (n ≥ 2). 
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2.2.6.2 Development of a radio-HPLC system for the identification of 
[18F]Fallypride and possible by-products. 
Radio-HPLC was performed on a LiChrospher 100-250 RP-18e column (5µm, 
250mm x 4.6mm). 20µL of the reaction mixture were injected into the HPLC system 
and separated using a gradient of acetonitrile (=eluent A) and 25mM ammonium 
formate buffer. (=eluent B) The gradient started at 40% A and was gradually 
increased to 60% A from minute 5 to 6. It was then kept at 60% A until minute 12. 
The column was re-equilibrated for 3 minutes to 40% A before starting the next HPLC 
analysis. The radioactive components of the reaction solution were detected using a 
NaI scintillation detector, while non-radiactive components were detected using a 
standard UV detector adjusted to a wavelength of 254nm. 
Due to its hydrophilicity, the [18F]fluoride ion was hardly retained and eluted almost 
immediately after injection into the column. (tR = 1.02 minutes). [
18F]Fallypride and 
the internal standard [19F]Fallypride eluted at tR=7.45 respectively tR = 7.48 minutes 
while the precursor tosyl-Fallypride eluted at tR = 11.00 minutes. 
  
Fig. 2.9: Sample chromatogram of the separation of [
18
F]Fluoride from [
18
F]Fallypride by radio-
HPLC 
 
[
19
F]Fallypride Tosyl-Fallypride 
[
18
F]fluoride [
18
F]Fallypride 
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3  Results 
All results are presented as decay-corrected radiochemical incorporation yields 
(RCIYs). 
3.1 Vessel-based synthesis of [18F]Fallypride 
A distinct dependency upon increasing reaction temperature was observed. Only little 
conversion (4.9±1.0%) was observed at 40°C for reactions at 5mg/mL precursor 
concentration in reaction mixture and 15min reaction duration.  
Highest radiochemical incorporation yields were achieved at 85°C (54±7%). Because 
the boiling point of acetonitrile is 81.6°C at atmospheric pressure, reactions 
conducted at this temperature were at risk of solvent evaporation. (see high standard 
deviations above 70°C) 
Reaction 
temperature (°C) Total mean yield (%) Standard deviation (%) 
40°C 4.9 1.0 
60°C 24.8 1.5 
70°C 36.1 12.5 
80°C 43.6 7.3 
85°C 54.3 7.0 
Table 3.1: Dependency of reaction yields upon reaction temperature at a constant precursor 
concentration of 5mg/mL, stirred for 15 minutes 
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Fig. 3.1: Dependency of conversion yields of [
18
F]Fallypride on reaction temperature at a 
constant precursor concentration of 5mg/mL, stirred for 15 minutes 
Dependency of reaction yields on precursor concentration and reaction duration were 
tested at 70°C and varying reaction durations of 2, 5, 15 and 30 minutes. Three 
different precursor concentrations of 1mg/mL, 2.5mg/mL and 5mg/mL were used. 
Mean conversion yields increased for all precursor concentrations with extension of 
the reaction time, reaching a maximum for precursor concentrations 1mg/mL and 
5mg/mL at a reaction time of 15 minutes.  
At a concentration of 2.5mg/mL, yields increased further when reaction duration was 
increased from 15 minutes to 30 minutes. (see Table 3.2 and Fig. 3.2) 
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Precursor concentration Reaction duration (min.) Total mean yield (%) Standard deviation (%) 
1mg/mL 2 2.4 1.9 
 
5 7.3 2.8 
 
15 16.5 3.4 
 
30 15.5 2.9 
2.5mg/mL 2 5.3 2.9 
 
5 19.8 6.1 
 
15 27.5 3.5 
 
30 35.6 4.2 
5mg/mL 2 6.6 3.0 
 
5 20.8 5.1 
 
15 36.1 12.5 
 
30 33.8 7.0 
Table 3.2: Dependency of conversion yields upon reaction duration and precursor 
concentration at a constant reaction temperature of 70°C 
Fig. 3.2: Dependency of conversion yields upon reaction duration with various precursor 
concentrations (1; 2.5; 5 mg/mL) at a reaction temperature of 70°C 
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3.2 Microfluidic synthesis of [18F]Fallypride 
Microfluidic reactions showed no radiochemical incorporation at a reaction 
temperature of 26°C regardless of the used precursor concentration. At a 
temperature of 100°C, no conversion was observed with precursor concentrations 
lower than 1mg/mL. Only little conversion was detected at precursor concentrations 
of 2.5mg/mL and 5mg/mL in the reaction mixture. (5.3±0.3% respectively 1.02±0.3%)  
At 140°C, conversion was achieved at all precursor concentrations and could be 
increased further by increasing the reaction temperature up to 180°C. (see Fig. 3.3). 
A distinct dependency upon the precursor concentration in the reaction mixture was 
also observed. 
Maximum yields (91.6±1.0% incorporation of [18F]fluoride) were observed at a 
precursor concentration of 2.5mg/mL, a reaction temperature of 180°C and an overall 
flow rate of 60µL/min (30µL/min per pump). 
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Precursor concentration Reaction temperature (°C) Total mean yield (%) Standard deviation (%) 
0.5mg/mL 26 0.0 0.0 
  100 0.0 0.0 
  140 17.5 2.3 
  150 12.9 3.0 
  160 16.2 0.9 
  170 57.4 10.5 
  180 56.5 1.4 
1mg/mL 26 0.0 0.0 
  100 0.0 0.0 
  140 25.2 5.3 
  150 35.9 12.6 
  160 72.3 7.4 
  170 72.9 9.8 
  180 79.4 9.7 
2.5mg/mL 26 0.0 0.0 
  100 5.3 0.3 
  140 47.3 1.0 
  150 64.7 2.2 
  160 79.7 1.6 
  170 88.0 1.5 
  180 91.6 1.0 
5mg/mL 26 0.0 0.0 
  100 1.0 0.3 
  140 15.7 1.2 
  150 38.3 8.9 
  160 53.8 7.9 
  170 81.5 1.0 
  180 86.1 1.1 
Table 3.3: Dependency of conversion upon reaction temperature and precursor concentration 
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Fig. 3.3: Dependency of reaction yields upon precursor concentration and reaction 
temperature at an overall flow rate of 60µL/min 
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4 Discussion 
Neither the evaluation of optimum reaction conditions regarding the synthesis of 
[18F]Fallypride nor an analysis directly comparing vessel-based and microfluidic 
preparation of this substance have been presented in literature before. 
Therefore, a direct comparison between these two approaches is presented here. 
Since the microfluidic synthesis of [18F]Fallypride has been reviewed by Lu et al. in 
2009 [78], the presented data will be compared with these results. 
4.1 Vessel-based synthesis of [18F]Fallypride 
The influence of reaction temperature on yields was investigated at a temperature of 
70°C and 15 minutes reaction duration. A distinct dependency of reaction yields upon 
reaction temperature was found. Yields fluctuated intensely at a reaction temperature 
of 70°C (standard deviation of ±12.5% from the mean yield, see Table 3.2).  
Mukherjee et al. (1995) reported synthesis yields varying from 20-40% at a precursor 
concentration of 20mg/mL (3mg tosylate in 150µL acetonitrile) over a temperature 
range of 85-90°C and reaction duration of 30 minutes in acetonitrile. [69]  
In a more recent work, Moon et al. (2010) were able to enhance radiochemical 
conversion by increasing the temperature and reducing the base component present 
in the reaction mixture. [79] They reported maximum conversion yields at 100°C and 
a reaction duration of 30 minutes (71±1.2%), but preferred the slightly lower yielding 
(68±1.6%) but faster reactions at 100°C and 10 minutes reaction duration.  
In contrast to the work of Mukherjee et al., detailed reaction conditions were 
specified. However, none of the conventional procedures achieved more than 72.4% 
of radiochemical conversion. 
In this work, maximum yields of 54.3±7.0% were found at a reaction temperature of 
85°C, a precursor concentration of 5mg/mL and reaction duration of 15 minutes. 
Due to the boiling point of acetonitrile (81.6°C at atmospheric pressure) reactions in 
acetonitrile can be problematic at this temperature, since solvent evaporation and 
radioactive contamination can occur if the reaction vessel is not tightly sealed. 
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The influence of precursor concentration and reaction duration on yields was tested 
at three different precursor concentrations of 1mg/mL, 2.5mg/mL and 5mg/mL at a 
reaction temperature of 70°C. This temperature was chosen deliberately due to the 
large yield fluctuations found during the temperature experiments (see chapter 3.1.1) 
to maximize the influence of factors other than reaction temperature on reaction 
yields.  
At a precursor concentration of 1mg/mL RCIYs were low, not exceeding 16.5±3.4% 
at 15 minutes reaction duration. Reactions at a precursor concentration of 2.5mg/mL 
showed a distinct dependency upon reaction duration, with yields constantly 
increasing from a duration of 2 minutes up to 30 minutes, showing peak yields of 
35.6±4.2% at reaction times of 30 minutes. 
Summing up, ideal reaction conditions for the vessel-based synthesis of 
[18F]Fallypride are a precursor concentration of 2.5mg/mL and a reaction duration of 
30 minutes, yielding 35.6±4.2% of the product [18F]Fallypride. Against expectations, 
an increase of precursor concentration from 2.5mg/mL to 5mg/mL did not result in 
substantial gain in reaction yields. Neither did an extension of reaction duration from 
15 to 30 minutes for precursor concentrations of 1mg/mL and 5mg/mL. 
4.2 Microfluidic synthesis of [18F]Fallypride 
The optimization of the microfluidic synthesis of [18F]Fallypride has been described 
recently by Lu et al. (2009) [78]. In this article, two different precursor concentrations 
(2mg/mL and 4mg/mL) were tested, while in the presented study four different 
precursor concentrations were examined. 
Reaction set-up was identical to the set-up used by Lu et al. In both set-ups, a 
microreactor of 2m length and 100µm diameter was used. The precursor to 
[18F]fluoride ratio was 1:1 (v/v%) in all examinations. Precursor concentrations and 
bolus sizes used were different. Lu et al. used a precursor concentration of 2mg/mL 
respectively 10µL bolus size, while in the present study concentrations 0.5mg/mL, 
1mg/mL, 2.5mg/mL and 5mg/mL with bolus sizes of 5-50µL were examined. 
Since the difference between used precursor concentrations is minimal, results from 
2.5mg/mL experiments from this study and 2mg/mL experiments presented in [78] 
will be compared. 
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The only difference between these set-ups was a back-pressure device, which was 
used in the presented work. This back-pressure device was placed behind the 
reactor to prevent solvent evaporation and boiling in the reactor at high temperatures. 
Lu et al. reported decay-corrected radiochemical yields of 0-65% over a temperature 
range of 100-170°C. We found radiochemical yields of 0% below 100°C at all 
precursor concentrations. Stable and very high radiochemical yields were found at a 
reaction temperature of 180°C, while Lu et al. reported erratic yields for temperatures 
above 170°C. The deviation obviously resulted from the missing back-pressure 
device after the reactor. 
Reaction temperature 2mg/mL (literature) 2.5mg/mL 
< 100°C 0% 0% 
100°C 0% 5.3±0.3% 
140°C ~38% 47.3±1.0% 
150°C ~40% 64.7±2.2% 
160°C ~60% 79.7±1.6% 
170°C ~65% 88.0±1.5% 
180°C erratic 91.6±1.0% 
Table 4.1: Comparison of literature data using 2mg/mL precursor concentration and presented 
data using 2.5mg/mL precursor concentration. 
The results indicate that only a precursor concentration of 2.5mg/mL produces stable 
and reproducible yields throughout the used temperature spectrum. Precursor 
concentrations below and also above 2.5mg/mL produced significant yield 
fluctuations at certain reaction temperatures.  
4.2.1 Difficulties encountered using the Advion NanoTek LF system 
Although the use of the Advion NanoTek LF system for radiosyntheses offers several 
advantages compared to conventional vessel-based synthesis, the system is still 
suffering from “teething troubles”.  
A problem encountered often was the clogging of reactors. Particulate impurities from 
solvents led to the congestion of the system, causing an over-pressure failure. The 
system automatically stopped all actions to prevent pump damage. To restore the 
system it was often necessary to run several time consuming cleaning steps to 
remove potential particulate contaminations. In some cases, it was not possible to re-
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open the reactor even after several cleaning runs. The reactor then had to be 
exchanged for a new one.  
Another problem with reactors occurred with a batch of new reactors that started to 
leak after several syntheses. These reactors did not withstand the pressures 
occurring during syntheses, causing the connection between the reactor capillary and 
the pump lines to break. These reactors were exchanged free of charge by the 
manufacturer. 
Additionally, the usability of the software interface (version 1.3.2) was not 
satisfactory, especially when programming routines in the proprierary programming 
language. This, however, has already been addressed in a recent software update. 
(version 1.4.0) 
4.3 Comparison between vessel-based and microfluidic approach  
Highest RCIYs of 54.3±7% were found at a precursor concentration of 5mg/mL at 
85°C and reaction duration of 15 minutes in the vessel-based approach. Since 
reactions were held under pressure (up to 400psi/28bar), reaction temperatures 
could be increased up to 180°C in the Advion NanoTek LF without causing the 
solvent to boil. The increased reaction temperature made conversion yields of 
91.6±1% at 2.5mg/mL precursor concentration in the reaction solution possible. The 
microfluidic approach overtops the results of the vessel-based synthesis approach by 
far. Also previously reported studies conducted with conventional set-ups, either 
automated [79] or manual [69], didn‟t reach such high conversion yields. 
While the vessel-based approach necessitated reaction volumes of at least 250µL of 
precursor solution, the microfluidic approach used very small reaction volumes 
starting from 5µL up to maximally 50µL, leading to a reduction of precursor usage in 
the range of 20% up to 98% in comparison with the vessel-based approach.  
In a typical optimization run using a precursor concentration of 2.5mg/mL, a minimum 
amount of 12.5µg (0.02µmol) up to a maximum amount of 125µg (0.2µmol) of 
precursor were applied. Reduction of precursor usage is an important advantage of 
this method, especially when rare or expensive precursor substances are used.  
Another benefit of microfluidic systems is the feasibility of reaction optimizations at a 
fraction of the time needed with conventional methods. From a single batch of 
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precursor and radionuclide, multiple individual reactions (up to 40 in our set-up) can 
be carried out without any further time-consuming preparation or cleaning steps. The 
limit is only set by the volume of the used storage loops and the amount of 
radioactivity per batch needed for reliable detection in the used chromatographic 
assays. Using the built-in discovery mode of the Advion NanoTek LF system, 
reaction conditions can be quickly varied, enabling the evaluation of optimum 
reaction conditions for a reaction in a very short period of time.  
When optimum reaction conditions have been established, reactions can be easily 
scaled up by using the batch mode to produce larger quantities of the desired 
radiotracer. Except from increasing the reaction volume, no changes in reaction 
parameters must be made for scaling up.  
It is also possible to directly connect the product outlet of the Advion NanoTek LF 
system to an HPLC system or SPE cartridge for in-line product purification, yielding a 
ready-to-use product. Also, the use of an HPLC/MS-coupling for product purification 
and subsequent product identification has been reported. 
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5 Summary and outlook 
During this diploma thesis, the synthesis and quality control of [18F]Fallypride using 
two different approaches has been established. Although there were many problems 
concerning the handling of the microfluidic system, the system demonstrated its 
superiority in achievable radiochemical conversion yields. Obviously, this emerging 
technique is still suffering from “teething problems”. Apart from these problems, the 
system offers the opportunity of unprecedented radiochemical conversion yields and 
shorter reaction times. The syntheses conducted with the microfluidic system overtop 
the results of the vessel-based synthesis approach by far: in terms of yields, 
precursor usage and reaction duration. 
For the vessel-based set-up, highest conversion yields of 54.3±7% were obtained at 
a precursor concentration of 5mg/mL and a reaction duration of 15 minutes at 85°C. 
At 70°C, reactions at a precursor concentration of 2.5mg/mL and a reaction duration 
of 30 minutes still yielded 35.6±4.2%, making this set-up the economically cheapest 
and thus most preferable. 
With 2.5mg/mL of precursor used, the microfluidic technique yielded 91.6±1.0% of 
the product at 180°C using a 60µL/min overall flow rate. Since the vessel-based 
approach did not show as high radiochemical yields as the microfluidic approach, 
only the latter was automated, making direct interaction unnecessary. This is a big 
advantage in terms of radiation protection. 
For the further use of [18F]Fallypride in clinical or animal studies, the preparative 
HPLC purification and galenic formulation of the radiotracer (both published in [80]) 
need to be established at the production site using available standard procedures. 
All in all, the successful implementation and optimization of the radiosynthesis of the 
important neuroimaging PET tracer, [18F]Fallypride, was achieved. 
  
 58 
 
6 Appendix: raw data 
Raw data sets of the experimental series performed are presented in table 6.1. 
Number of 
table 
Description 
 Vessel-based syntheses 
6.2 Influence of reaction temperature on synthesis yields 
6.3 Influence of precursor concentration and reaction duration on 
synthesis yields (1mg/mL tosyl-Fallypride) 
6.4 Influence of precursor concentration and reaction duration on 
synthesis yields (2.5mg/mL tosyl-Fallypride) 
6.5 Influence of precursor concentration and reaction duration on 
synthesis yields (5mg/mL tosyl-Fallypride) 
 Microfluidic syntheses 
6.6 Dependency of reaction yields on precursor concentration and 
reaction temperature (0,5mg/mL tosyl-Fallypride) 
6.7 Dependency of reaction yields on precursor concentration and 
reaction temperature (1mg/mL tosyl-Fallypride) 
6.8 Dependency of reaction yields on precursor concentration and 
reaction temperature (2.5mg/mL tosyl-Fallypride) 
6.9 Dependency of reaction yields on precursor concentration and 
reaction temperature (5mg/mL tosyl-Fallypride) 
Table 6.1: Overview of the raw data sets. 
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Table 6.2: Vessel-based approach: influence of reaction temperature with 5mg/mL tosyl-Fallypride and 15 minutes reaction duration   
Temp. (°C) Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) Standard deviation (%) 
40 5.10 4.80 4.95 4.87 0.99 
40 6.50 6.10 6.30 
  
40 3.70 3.40 3.55 
  
40 4.70 5.30 5.00 
  
40 4.50 4.60 4.55 
  
60 23.80 29.60 26.70 24.81 1.52 
60 25.40 25.80 25.60 
  
60 22.40 24.20 23.30 
  
60 27.30 23.20 25.25 
  
60 23.60 22.80 23.20 
  
60 23.60 22.80 23.20 
  
70 26.10 23.80 24.95 36.09 12.45 12.45 
70 24.50 22.30 23.40 
  
 
70 25.50 26.20 25.85 
  
 
70 47.80 52.20 50.00 
  
 
70 45.30 48.80 47.05 
  
 
70 51.80 55.00 53.40 
  
 
70 45.50 46.20 45.85 
  
 
70 44.30 47.40 45.85 
  
 
70 36.50 33.60 35.05 
  
 
70 23.40 24.10 23.75 
  
 
70 22.90 20.80 21.85 
  
 
85 44.20 45.70 44.95 54.26 6.98 
85 56.60 54.60 55.60 
  
85 54.10 57.70 55.90 
  
85 44.20 47.90 46.05 
  
85 47.90 45.60 46.75 
  
85 64.70 57.00 60.85 
  
85 54.60 55.20 54.90 
  
85 56.30 60.60 58.45 
  
85 68.30 61.50 64.90 
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Temp. (°C) Reaction duration (min.) Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) Standard deviation (%) 
70 2 2.80 2.60 2.70 2.43 1.85 
70 2 4.10 4.90 4.50 
  
70 2 4.10 5.30 4.70 
  
70 2 0.00 0.50 0.25 
  
70 2 1.70 2.10 1.90 
  
70 2 0.40 0.60 0.50 
  
70 5 11.00 11.90 11.45 7.26 2.83 
70 5 9.50 10.30 9.90 
  
70 5 8.00 7.60 7.80 
  
70 5 4.50 4.30 4.40 
  
70 5 4.50 5.00 4.75 
  
70 5 5.70 4.80 5.25 
  
70 15 19.70 21.70 20.70 16.52 3.39 
70 15 14.60 14.30 14.45 
  
70 15 15.60 13.20 14.40 
  
70 30 18.20 18.40 18.30 15.49 2.91 
70 30 10.70 12.80 11.75 
  
70 30 15.70 18.70 17.20 
  
70 30 13.80 15.60 14.70 
  Table 6.3: Vessel-based approach: influence of reaction duration with 1mg/mL tosyl-Fallypride stirred at 70°C 
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Temp. (°C) Reaction duration (min.) Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) Standard deviation (%) 
70 2 2.5 3.6 3.05 5.27 2.93 
70 2 2.3 2.7 2.5 
  
70 2 5.9 6.9 6.4 
  
70 2 8.5 11.1 9.8 
  
70 2 5.8 3.4 4.6 
  
70 5 23.9 32.4 28.15 19.78 6.07 
70 5 24.4 28.2 26.3 
  
70 5 15.7 16.3 16 
  
70 5 17.1 15.2 16.15 
  
70 5 19.6 16.9 18.25 
  
70 5 14.5 13.2 13.85 
  
70 15 24.3 24.7 24.5 27.47 3.51 
70 15 29.1 26.9 28 
  
70 15 22.6 24.7 23.65 
  
70 15 28.2 27 27.6 
  
70 15 31.7 34.5 33.1 
  
70 15 30.7 25.2 27.95 
  
70 30 26.2 35.4 30.8 35.58 4.20 
70 30 35.7 33.9 34.8 
  
70 30 38.4 39.1 38.75 
  
70 30 37.2 38.7 37.95 
  Table 6.4: Vessel-based approach: Influence of reaction duration with 2.5mg/mL tosyl-Fallypride stirred at 70°C 
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Temp. (°C) Reaction duration (min.) Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) Standard deviation (%) 
70 2 11.40 10.40 10.90 6.58 2.98 
70 2 8.30 8.60 8.45 
  70 2 6.70 5.60 6.15 
  70 2 3.90 3.60 3.75 
  70 2 2.90 2.90 2.90 
  70 2 7.40 7.20 7.30 
  70 5 22.50 24.30 23.40 20.82 5.14 
70 5 21.00 21.40 21.20 
  70 5 14.20 13.40 13.80 
  70 5 20.80 15.80 18.30 
  70 5 28.10 26.70 27.40 
  70 15 26.10 23.80 24.95 36.09 12.45 
70 15 24.50 22.30 23.40 
  70 15 25.50 26.20 25.85 
  70 15 47.80 52.20 50.00 
  70 15 45.30 48.80 47.05 
  70 15 51.80 55.00 53.40 
  70 15 45.50 46.20 45.85 
  70 15 44.30 47.40 45.85 
  70 15 36.50 33.60 35.05 
  70 15 23.40 24.10 23.75 
  70 15 22.90 20.80 21.85 
  70 30 38.50 45.50 42.00 33.81 6.98 
70 30 40.80 40.70 40.75 
  70 30 28.20 29.60 28.90 
  70 30 26.80 28.00 27.40 
  70 30 28.60 31.40 30.00 
  Table 6.5: Vessel-based approach: influence of reaction duration with 5mg/mL tosyl-Fallypride stirred at 70°C   
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Table 6.6: Microfluidic approach: dependency of reaction yields upon reaction temperature at a constant precursor concentration of 0.5mg/mL tosyl-
Fallypride in the reaction mixture and 60µL/min overall flow rate  
Temp. (°C) Precursor concentratipn Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) 
Standard 
deviation (%) 
26 0.5mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
100 0.5mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
140 0.5mg/mL 19.40 19.20 19.30 17.53 2.28 
  
15.20 14.10 14.65 
  
  
18.60 18.70 18.65 
  
150 0.5mg/mL 16.00 17.40 16.70 12.92 2.98 
  
10.90 11.60 11.25 
  
  
11.10 10.50 10.80 
  
160 0.5mg/mL 17.80 16.20 17.00 16.22 0.89 
  
15.80 15.20 15.50 
  
  
16.50 15.80 16.15 
  
170 0.5mg/mL 71.60 68.40 70.00 57.43 10.48 
  
55.00 55.60 55.30 
  
  
46.40 47.60 47.00 
  
180 0.5mg/mL 57.80 58.40 58.10 56.53 1.40 
  
56.20 54.80 55.50 
  
  
56.70 55.30 56.00 
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Table 6.7: Microfluidic approach: dependency of reaction yields upon reaction temperature at a constant precursor concentration of 1mg/mL tosyl-
Fallypride in the reaction mixture and 60µL/min overall flow rate  
Temp. (°C) Precursor concentration Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) 
Standard 
deviation (%) 
26 1mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
100 1mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
140 1mg/mL 25.00 29.50 27.25 25.15 5.26 
  
25.00 31.30 28.15 
  
  
16.20 23.90 20.05 
  
150 1mg/mL 21.50 25.20 23.35 35.93 12.57 
  
38.70 55.10 46.90 
  
  
31.00 44.10 37.55 
  
160 1mg/mL 80.70 82.40 81.55 72.25 7.41 
  
66.90 67.00 66.95 
  
  
65.80 70.70 68.25 
  
170 1mg/mL 63.80 76.90 70.35 72.87 9.79 
  
58.20 84.30 71.25 
  
  
76.30 77.70 77.00 
  
180 1mg/mL 69.60 66.70 68.15 79.37 9.72 
  
85.90 92.30 89.10 
  
  
79.70 82.00 80.85 
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Table 6.8: Microfluidic approach: dependency of reaction yields upon reaction temperature at a constant precursor concentration of 2.5mg/mL tosyl-
Fallypride in the reaction mixture and 60µL/min overall flow rate  
Temp. (°C) Precursor concentration Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) Standard deviation (%) 
26 2.5mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
100 2.5mg/mL 5.40 5.80 5.60 5.32 0.33 
  
5.00 5.50 5.25 
  
  
4.90 5.30 5.10 
  
140 2.5mg/mL 48.70 48.10 48.40 47.32 0.95 
  
46.20 46.50 46.35 
  
  
47.10 47.30 47.20 
  
150 2.5mg/mL 66.70 61.10 63.90 64.65 2.19 
  
65.60 62.80 64.20 
  
  
66.00 65.70 65.85 
  
160 2.5mg/mL 80.30 80.20 80.25 79.68 1.59 
  
77.50 77.90 77.70 
  
  
81.10 81.10 81.10 
  
170 2.5mg/mL 89.90 89.80 89.85 87.98 1.51 
  
86.80 87.90 87.35 
  
  
86.70 86.80 86.75 
  
180 2.5mg/mL 90.80 90.60 90.70 91.57 0.99 
  
91.10 92.00 91.55 
  
  
93.30 91.60 92.45 
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Table 6.9: Microfluidic approach: dependency of reaction yields upon reaction temperature at a constant precursor concentration of 5mg/mL tosyl-
Fallypride in the reaction mixture and 60µL/min overall flow rate 
Temp. (°C) Precursor concentration Yield TLC 1 (%) Yield TLC 2 (%) Mean yield (%) Total mean yield (%) 
Standard deviation 
(%) 
26 5mg/mL 0.00 0.00 0.00 0.00 0.00 
  
0.00 0.00 0.00 
  
  
0.00 0.00 0.00 
  
100 5mg/mL 0.50 0.90 0.70 1.02 0.30 
  
1.10 1.40 1.25 
  
  
1.10 1.10 1.10 
  
140 5mg/mL 14.50 15.20 14.85 15.70 1.18 
  
16.90 16.90 16.90 
  
  
14.30 16.40 15.35 
  
150 5mg/mL 26.50 27.50 27.00 38.32 8.91 
  
43.00 45.20 44.10 
  
  
46.10 41.60 43.85 
  
160 5mg/mL 52.40 38.60 45.50 53.82 7.88 
  
59.20 55.70 57.45 
  
  
58.00 59.00 58.50 
  
170 5mg/mL 81.50 79.60 80.55 81.50 0.98 
  
81.90 82.20 82.05 
  
  
82.20 81.60 81.90 
  
180 5mg/mL 87.40 87.00 87.20 86.12 1.09 
  
85.30 84.70 85.00 
  
  
86.80 85.50 86.15 
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